Nivolumab/Relatlimab Combo Improves PFS in Advanced Melanoma

Source: Targeted Oncology, January 2022

Efficacy was seen with blocking LAG-3 in combination with PD-1 as a therapeutic strategy for patients with melanoma. Additionally, this research establishes LAG-3 as the third immune checkpoint pathway to have proven clinical benefit in this patient population.

The combination of relatlimab and nivolumab (Opdivo) for untreated advanced melanoma significantly improves progression-free survival (PFS) compared with nivolumab monotherapy, according to a phase 2/3 study conducted by MD Anderson Cancer Center and published in The New England Journal of Medicine.^1,2

Both LAG-3 and PD-1 are upregulated in melanoma, leading to T-cell exhaustion. Relatlimab is a LAG-3 inhibitor and nivolumab is an anti-PD-1, supporting their combination in this patient population.

READ THE ORIGINAL FULL ARTICLE